TORONTO, Oct. 25 /PRNewswire/ -- Dalton Chemical Laboratories, Inc., a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced it has completed Phase III of its facilities expansion.
Bringing its total investment in the Wildcat site to over $7 million, the $1.4 million expansion includes a Peptide Production Laboratory, a Microbiology Laboratory, a QA Sampling Suite, an Oligonucleotide Production Suite, a Back Up Generator and a UPS system.
"We are pleased to continue to add to our world class research and manufacturing facilities for our Canadian and worldwide customer base. Pharmaceutical Development is a tremendous area to be in right now as many exciting new approaches to treat disease are coming to fruition. By providing medicinal chemistry, integrated GMP synthesis and sterile fill in the same facility, Dalton can now reduce the development time for our clients dramatically," states Peter Pekos, President and CEO.
The Peptide Laboratory accommodates a variety of peptide synthesis, purification and analysis equipment from micro scale to hundred gram production scale. The space is equipped with two walk-in fume hoods, a bench top fume hood and a separate, negatively pressured solvent removal room.
Dalton's in house microbial monitoring capabilities have been expanded with the new Microbiology Laboratory. It is outfitted for biohazard safety level 2 conditions with a variety of incubators and biohazard hoods to ensure safe handling and processing.
Our Oligonucleotide Production Suite is equipped with the latest technology that allows small to large scale Oligo production and purification capabilities. Our equipment includes 4 AKTA OligoPilots each capable of producing 50g of oligo per run.
The addition of a state of the art regulated QA Sampling Suite equipped with the latest monitoring and safety devices is a key step in Dalton's GMP compliance.
A back up generator that can support a facility twice Dalton's current size was installed to ensure that Dalton's production will continue during any main grid malfunctions. Installation of a new Uninterruptible Power Supply ensures that all critical GMP and analytical equipment at Dalton is protected from any power fluctuation.
About Dalton Chemical Laboratories, Inc.
Dalton Chemical Laboratories Inc. is a contract pharmaceutical manufacturer that supplies chemistry and analytical services to the biotechnology and pharmaceutical industries in the areas of medicinal chemistry, fine chemical manufacture, custom peptides and antisense oligo production. Dalton provides cGMP manufacturing and sterile filling capabilities to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton can produce active pharmaceutical ingredients (API), at the gram or kilogram scale. Dalton can carry out sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. Dalton has a Site Establishment License and is registered with Health Canada as a drug testing lab.
Dalton Chemical Laboratories Inc.